MARKSANS

** India's Marksans Pharma MARK.NS rises 5%

** Co says Goa facility gets Australian nod for exports

** Stock set for third consecutive session of gains

** More than 1.7 mln shares change hands, 1.2x of 30-day avg

** Stock cuts YTD loss to ~27%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

March 19 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - RELONCHEM RECEIVES UK MHRA APPROVAL FOR BACLOFEN 10 MG TABLETS

Source text: ID:nBSE8NR31v

Further company coverage: MARK.NS

(([email protected];))

Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD- UK UNIT GETS MARKETING AUTHORIZATION FOR PRODUCT IBUPROFEN AND PARACETAMOL

Source text: [ID:]

Further company coverage: MARK.NS

Feb 11 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES

• MARKSANS PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.82 BILLION RUPEES

Source text: ID:nBSE7GJBDX

Further company coverage: MARK.NS

(([email protected];))

Nov 22 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA - USFDA APPROVAL FOR LORATADINE USP 10MG TABLETS

Source text: [ID:]

Further company coverage: MARK.NS

(([email protected];))

Nov 12 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA SEPT-QUARTER CONSOL NET PROFIT 967.2 MILLION RUPEES

• MARKSANS PHARMA SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES

Source text: ID:nNSE1WZ3QZ

Further company coverage: MARK.NS

(([email protected];;))

Aug 21 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - UNIT RELONCHEM RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS

• MARKSANS PHARMA - UNIT GETS MARKETING AUTHORIZATION FOR FLUOXETINE 10MG, 30MG, 60MG CAPSULES

Source text for Eikon: [ID:]

Further company coverage: MARK.NS

(([email protected];;))

Aug 20 (Reuters) - Marksans Pharma Ltd MARK.NS:

• CLOSURE OF FDA INSPECTION AT MANUFACTURING FACILITY IN VERNA, GOA

• USFDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR MANUFACTURING FACILITY

• INSPECTION CLASSIFICATION OF FACILITY IS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE427rPg

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS up 9.4% at 205.4 rupees, its steepest gain since July 24

** Pharmaceutical formulations maker's Q1 consol net profit grew ~30%, rev up 18%

** Shares see busiest day in about 3 weeks, with over 3.2 mln shares traded

** Stock up 28% YTD, vs an 81% and 9% rise in peers Natco Pharma NATP.NS and Mankind Pharma MNKI.NS, respectively

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Aug 13 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 887.5 MILLION RUPEES

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.91 BILLION RUPEES

Source text for Eikon: ID:nBSEbkbfV1

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS up 2.1% to 167.21 rupees

** Pharmaceutical firm says its unit got marketing authorisation from UK MHRA for four products

** Stock was down 0.8% before the announcement

** MARK up ~4% YTD, rival Pfizer PFIZ.BO up ~8% and IOL Chemicals and Pharmaceuticals IOLC.BO down ~6%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of Marksans Pharma MARK.NS slide 11.4%

** Stock set for biggest one-day drop since March 2020

** Drugmaker posts 4.5% Y/Y fall in Q4 profit

** Rev rises 15.2%, but is outpaced by costs jumping 21.3%

** Stock reverses course to YTD losses; now down ~5% YTD

** Stock had surged ~177% in 2023, its best year since 2020

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected]))

** Shares of Marksans Pharma MARK.NS rose as much as 2.8%; last up 0.9% to 166.2 rupees

** Co's unit got marketing authorisation from UK drug regulator for Levetiracetam Relonchem 100 mg/mL oral solution used in seizure treatment

** Stock on track for second straight monthly climb, up 1.5% in May after falling for four straight months through March

** Stock up ~3% YTD vs ~13% climb in Nifty Pharma index .NIPHARM, of which MARK is not a member

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

April 18 (Reuters) - Marksans Pharma Ltd MARK.NS:

• USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN VERNA, GOA, INDIA

• COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483

• THERE IS NO DATA INTEGRITY OBSERVATION

Further company coverage: MARK.NS

(([email protected];))

Feb 13 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 832.4 MILLION RUPEES VERSUS 634.1 MILLION RUPEES

• MARKSANS PHARMA LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.86 BILLION RUPEES VERSUS 4.8 BILLION RUPEES

Source text for Eikon: ID:nNSE9j7rXt

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS rise as much as 10.5% to hit a record high of 128.50 rupees

** Stock marks sharpest intraday pct gain since July 26

** The drugmaker reported a 36.3% Y/Y rise in Q2 consolidated net profit while rev from ops rose 17.3% Y/Y

** EBITDA in Q2 grew by 41.9% with an EBITDA margin of 21.4%

** Operating margins expanded, compared with prior year, and sequentially led by reduced raw material pricing and freight cost, said MD and CEO Mark Saldanha

** Stock is witnessing its most active trading session since July 12, with more than 14.3 mln shares change hands, 8x of 30-day avg

** Marksans stock up ~120% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Marksans Pharma MARK.NS rise as much as 3.6% to 116.65 rupees apiece

** Drug maker's unit receives marketing authorisation from United Kingdom for Cyanocobalamin tablets

** Drug used to treat Vitamin B12 deficiencies and anaemia

** Trading volume is 2.87 mln shares as of 1:13 p.m. IST, nearly twice the 30-day avg - LSEG data

** Including day's gains, MARK up 99% in 2023 so far

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 3 (Reuters) - Marksans Pharma Ltd MARK.NS:

• TIME-CAP LABORATORIES, INC, RECEIVES ESTABLISHMENT INSPECTION REPORT FROM US FDA

• NO 483' S WERE ISSUED DURING THE AUDIT

Source text for Eikon: ID:nNSE3Ymvl2

Further company coverage: MARK.NS

(([email protected];;))

Nov 1 (Reuters) - Marksans Pharma Ltd MARK.NS:

• CO'S MANUFACTURING FACILITY HAS UNDERGONE INSPECTION FROM GERMAN HEALTH AUTHORITIES

• AUTHORITIES HAVE NOT FOUND ANY CRITICAL OR MAJOR OBSERVATIONS

Source text for Eikon: ID:nNSE1MPrh0

Further company coverage: MARK.NS

(([email protected];))

Oct 3 (Reuters) - Marksans Pharma Ltd MARK.NS:

• US FDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG (OTC)

Further company coverage: MARK.NS

(([email protected];))

Aug 22 (Reuters) - Marksans Pharma Ltd MARK.NS:

• RECEIVES USFDA APPROVAL FOR GUAIFENESIN EXTENDED-RELEASE TABLETS

Source text for Eikon: [ID:]

Further company coverage: MARK.NS

(([email protected];))

Aug 11 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 686.6 MILLION RUPEES VERSUS 597.2 MILLION RUPEES

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5 BILLION RUPEES VERSUS 4.34 BILLION RUPEES

Source text for Eikon: ID:nBSE5zjTZf

Further company coverage: MARK.NS

(([email protected];))

Aug 7 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS ANNOUNCES COMPLETION OF US FDA POST-MARKETING ADVERSE DRUG EXPERIENCE INSPECTION

• INSPECTION CLOSED WITH TWO OBSERVATIONS

• INSPECTION WAS CONDUCTED AT ITS GOA, VERNA MANUFACTURING FACILITY

Source text for Eikon: ID:nNSE7TFBYC

Further company coverage: MARK.NS

(([email protected];))

July 12 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS ANNOUNCES FDA APPROVAL OF OTC EQUIVALENT OF ADVIL DUAL ACTION TABLETS

• ANDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS

Source text for Eikon: ID:nBSE5w4qBL

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma Ltd MARK.NS climb as much as 11.16% to a 21-month high of 84.20 rupees

** Pharmaceuticals firm reports net profit that nearly triples Y/Y to 819.4 mln rupees in March quarter, revenue from operations up 16%

** Gains in existing store brands, products, normalisation of freight expenses aided consistent quarterly performance - CEO Mark Saldanha

** Adds recent acquisition of Teva Pharma manufacturing unit in Goa will accelerate growth

** Expect net interest margin (NIM) to be stable at 4.7% in FY24 and FY25, says Phillip Capital

** Adds risk-reward appears favourable at current valuations

** Trading volume is 14.40 mln shares as of 2:28 p.m. IST, more than eight times the 30-day avg - Refinitiv data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))